What Is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s. It is a stabilized analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from IgG immunoglobulins — with three additional amino acids (Pro-Gly-Pro) added to extend metabolic stability.
Selank has been officially registered in Russia as an anxiolytic drug (trade name “Selank,” registration №LSR-002602/08) and is legally available in Russia and several CIS countries as a prescription nasal spray. This places it in a different evidentiary category from many research peptides: it has undergone formal Phase 1–3 clinical development.
The caveat: most of the clinical research was conducted in Russia, published primarily in Russian-language journals, and has not been replicated in Western peer-reviewed trials. Interpreting this evidence requires careful attention to publication standards and study design.
Mechanism of Action
Selank operates through several distinct but interconnected pathways:
GABA System Modulation
The primary anxiolytic mechanism appears to involve modulation of GABAergic neurotransmission. Research from the Institute of Molecular Genetics shows Selank increases the expression of GABA-A receptor subunits, particularly the α1 subunit, which is associated with anxiolytic and sedative effects.
Crucially, Selank appears to do this without directly binding to benzodiazepine sites on GABA-A receptors — a finding that may explain its lack of benzodiazepine-typical side effects (dependency, tolerance, sedation, cognitive impairment) in clinical studies.
Serotonin System Effects
Selank increases serotonin metabolism in the brain by upregulating tryptophan hydroxylase and monoamine oxidase A (MAO-A) activity. This increases turnover of serotonin — a finding that appears counterintuitive (MAO-A inhibitors are used as antidepressants) but may reflect a normalizing or regulatory effect on serotonergic tone rather than simple suppression.
BDNF Upregulation
Selank consistently upregulates brain-derived neurotrophic factor (BDNF) expression in animal studies. BDNF is critical for neuroplasticity, learning, and memory consolidation, and its upregulation may underlie the cognitive-enhancing (nootropic) claims made for Selank.
Enkephalin Degradation Inhibition
Selank inhibits the enzymatic degradation of enkephalins — endogenous opioid peptides involved in stress response modulation. By extending enkephalin half-life, Selank may enhance endogenous stress-buffering capacity without exogenously activating opioid receptors.
Immune System Interaction
As a tuftsin analogue, Selank retains some of tuftsin’s immunomodulatory properties. Tuftsin activates macrophages and natural killer cells. Selank has been studied for potential applications in immunodeficiency states, particularly in combination with antiviral medications.
Clinical Evidence: What the Studies Show
Anxiety and Generalized Anxiety Disorder (GAD)
The most robust clinical data comes from Phase 3 trials conducted for Selank’s Russian drug registration:
Key trial: A randomized, double-blind, placebo-controlled trial (Semenova et al.) comparing Selank intranasal spray (400 mcg/day) to oxazepam (a benzodiazepine) and placebo in 62 patients with generalized anxiety disorder over 14 days. Results:
- Selank reduced Hamilton Anxiety Scale (HAM-A) scores by 39% vs. baseline
- Oxazepam reduced HAM-A by 41% — not significantly different from Selank
- Placebo reduced HAM-A by 12%
- Key finding: Selank showed equivalent anxiolytic efficacy to oxazepam without the sedation, cognitive impairment, or withdrawal symptoms associated with benzodiazepine treatment
A follow-up trial in 60 patients with anxiety-asthenic disorders found similar results: significant HAM-A reduction vs. placebo, with improved working memory and attention measures compared to baseline (benzodiazepine comparator worsened these cognitive metrics).
Limitation: These trials are the primary clinical evidence base. They are relatively small, conducted by the developing institution, and published predominantly in Russian journals. Independent replication in Western settings has not occurred.
Cognitive Effects (Nootropic Claims)
Several smaller Russian studies examined Selank’s effects on cognitive function in healthy volunteers and patients with anxiety:
- Memory consolidation: Animal studies show improved performance on Barnes maze and Morris water maze tasks, consistent with BDNF upregulation
- Human cognitive studies: Some reports of improved attention, working memory, and learning speed in healthy volunteers at 400–900 mcg/day intranasal dosing
- Neuroimaging: EEG studies show Selank increases α-wave activity, associated with alert relaxation — a pattern distinct from benzodiazepine effects (which increase β-waves)
The human cognitive enhancement data is weak by Western evidence standards — small studies, often uncontrolled, in the grey zone between pharmaceutical research and nootropic documentation.
Post-Viral and Immune Applications
A Russian study of 60 patients with various viral infections found Selank (combined with standard antiviral care) showed significant improvement in immunological markers compared to standard care alone. The relevance to healthy populations and the generalizability of this finding is limited.
Comparison to Semax (Related Peptide)
Selank is often discussed alongside Semax (another Russian-developed nootropic peptide). The key distinction:
| Selank | Semax | |
|---|---|---|
| Primary effect | Anxiolytic, calming | Activating, stimulating |
| BDNF effect | Upregulates | Strongly upregulates |
| GABAergic | Yes | Minimal |
| Typical user report | Reduces anxiety, mild cognitive clarity | Increases focus, motivation, energy |
| Clinical development | Registered Russian drug (anxiolytic) | Registered Russian drug (neuroprotective) |
Users who find Semax overstimulating often report Selank as better tolerated. The two are sometimes combined (colloquially called “SELMAX”) in the nootropic community.
Administration and Dosing
Registered formulation (Russia): Intranasal spray, 0.15% solution (150 mcg per 100 mcL drop).
Typical research dosing:
- Intranasal: 250–900 mcg/day, divided across 2–3 applications
- Some research protocols use 500–1000 mcg/day for anxiety indications
- Duration of clinical trials: typically 10–14 days
Route considerations: Intranasal delivery bypasses the blood-brain barrier via olfactory nerve pathways and provides rapid CNS exposure. Subcutaneous injection is also used in research settings. Oral bioavailability is very low due to rapid peptide degradation in the GI tract.
Onset: Most studies report noticeable anxiolytic effects within 20–60 minutes of intranasal administration.
Half-life: Short — approximately 1–3 minutes in plasma due to enzymatic degradation. The Pro-Gly-Pro extension improves this vs. tuftsin but it remains a short-acting peptide. Effects may outlast plasma half-life due to receptor-level or gene expression changes.
Safety Profile
Selank’s safety data comes primarily from its Russian clinical development:
Short-term (14–28 days): Generally well-tolerated. The most common adverse effects are mild and local:
- Nasal irritation or congestion with intranasal use
- Occasional mild headache
- Rare: transient drowsiness
Notably absent from clinical reports:
- Sedation at therapeutic doses (unlike benzodiazepines)
- Cognitive impairment
- Dependence or withdrawal syndrome
- Changes in liver function, hematology, or vital signs
Longer-term: No long-term safety data exists from controlled trials. The registered product is intended for short-course use (typically 10–14 day cycles).
Drug interactions: Limited data. Potential additive effects with other anxiolytics or CNS depressants warrants caution. MAO-A interaction noted in mechanism data — theoretical interaction with MAO inhibitor medications.
Legal and Regulatory Status
| Jurisdiction | Status |
|---|---|
| Russia | Approved prescription anxiolytic (Selank® nasal spray) |
| USA | Not FDA approved. Research chemical status. No approved human use indication |
| EU | Not approved by EMA. No European marketing authorization |
| UK | Not approved by MHRA. Not listed as controlled substance |
| Canada | Not approved by Health Canada |
| Australia | Not TGA approved |
Outside Russia and CIS countries, Selank exists in legal grey territory — not scheduled as a controlled substance in most Western jurisdictions, but also not approved for any human use indication. This means sourcing is through research chemical suppliers, with associated quality control concerns.
What Remains Unknown
The gaps in the Selank evidence base are significant:
-
Independent replication: No Western Phase 2 or 3 trials have been published. All clinical evidence is from Russian studies, often by the developing institution.
-
Long-term effects: No data on chronic use beyond 28 days in controlled settings.
-
Optimal dosing: The 400–900 mcg/day intranasal range comes from a narrow set of trials. Dose-response relationships not fully characterized.
-
Mechanism confirmation: The GABAergic and serotonergic mechanisms are primarily from animal studies and Russian preclinical work. Independent mechanistic confirmation in humans is lacking.
-
Cognitive enhancement in healthy subjects: The nootropic evidence in healthy (non-anxious) individuals is anecdotal or from very small studies.
-
Comparison to current standard of care: No head-to-head trials vs. SSRIs, SNRIs, or modern psychotherapy for GAD.
Honest Assessment
Selank occupies an unusual position in the peptide research space: it has more formal clinical evidence than most research peptides (actual drug registration trials) but comes from a research tradition with limited Western peer review and independent replication.
The anxiolytic evidence is more credible than many nootropic claims — the Phase 3 comparison against oxazepam, showing similar efficacy with better tolerability, is a meaningful finding if it replicates. The cognitive enhancement data is much thinner and relies heavily on mechanism-of-action extrapolation.
For anyone evaluating Selank, the honest summary is: promising anxiolytic signals from Phase 3 Russian trials, with a favorable short-term safety profile, but Western replication is needed before this can be considered established evidence.
This guide is for educational and research purposes only. Selank is not approved for human use outside Russia. Nothing here constitutes medical advice, and this information should not guide clinical decisions without consultation with a qualified healthcare provider.
Found this useful? Share it with someone who'd benefit.